Chemed primary-filing facts: income and cash

Peralta factual exhibit | reconstructed rows; original publisher files accompany edition

FY2025 revenue 2529.978 USD million; FY2024 2431.287; FY2023 2264.417.

FY2025 EBIT 338.246 USD million; FY2024 366.493; FY2023 340.569.

FY2025 net income 265.238 USD million; diluted EPS 18.34 USD.

FY2025 CFO 388.272 USD million; capex 62.795; buybacks 431.500.

9M26 revenue 2021.704 USD million; 9M25 1890.641.

9M26 EBIT 270.204 USD million; 9M25 237.592.

9M26 net income 205.653 USD million; 9M25 188.487.

9M26 CFO 229.622 USD million; 9M25 254.739.

9M26 capex 51.355 USD million; acquisitions 96.050.

9M26 buybacks 350.042 USD million; dividends 25.234.

9M26 accounts receivable cash use 71.304 USD million.

9M26 net revolving credit draw 236.000 USD million.

SEC Chemed 2025 10-K statements pp.43-45; 2026 Q3 10-Q statements pp.3-5.

Verify figures in original filings and source index; this exhibit is not the original filing.

Chemed primary-filing facts: two businesses

Peralta factual exhibit | reconstructed rows; original publisher files accompany edition

FY2025 VITAS revenue 1630.101 USD million; Roto-Rooter 899.877.

9M26 VITAS revenue 1320.762 USD million; Roto-Rooter 700.942.

9M26 VITAS patient days 6448004; 9M25 6086983.

Q3 2026 VITAS average daily census 24428; growth 9.4 percent.

Q3 2026 VITAS net revenue 457.403 USD million.

Q3 2026 Medicare cap charge 0.828 USD million; Q3 2025 6.086.

9M26 Medicare cap charge 3.703 USD million; 9M25 24.786.

9M26 VITAS adjusted EBITDA 240.138 USD million.

9M26 Roto-Rooter adjusted EBITDA 150.125 USD million.

Q3 2026 Roto-Rooter revenue 233.537 USD million; growth 7.5 percent.

Q3 2026 Roto-Rooter adjusted EBITDA margin 20.6 percent; down 213 bp.

RotoCo franchise acquisition 60.6 USD million, funded by revolver.

SEC Chemed 2026 Q3 10-Q segment tables and MD&A pp.31-34; Q3 earnings release.

Verify figures in original filings and source index; this exhibit is not the original filing.

Chemed primary-filing facts: claims and ownership

Peralta factual exhibit | reconstructed rows; original publisher files accompany edition

September 2026 cash 48.427 USD million; debt 236.000.

September 2026 leases 156.194 USD million; ROU asset 144.029.

September 2026 deferred-comp trust 144.845; liability 142.421.

September 2026 capital shares outstanding 13.014915 million.

Q3 2026 diluted average shares 13.135 million; Q3 2025 14.409.

FY2025 Vanguard beneficial ownership 1.699648 million; 11.28 percent.

FY2025 BlackRock beneficial ownership 1.409958 million; 9.4 percent.

CEO son employed in strategy role; 2026 proxy disclosure p.46.

FY2027 CMS hospice payment update 2.3 percent.

SEC Chemed 2026 Q3 10-Q pp.3-4; 2026 proxy p.46; CMS FY2027 final rule.

Verify figures in original filings and source index; this exhibit is not the original filing.

Market observations and peer denominators

Peralta factual exhibit | reconstructed rows; original publisher files accompany edition

CHE NYSE unadjusted close 563.09 USD on 2026-11-25.

Bank of Canada USD/CAD daily average 1.4219 on 2026-11-25.

ADUS 2025 diluted EPS 5.22 USD; November 25 close 122.53 USD.

ROL 2025 diluted EPS 1.09 USD; November 25 close 38.45 USD.

CHE 2025 diluted EPS 18.34 USD; November 25 close 563.09 USD.

Yahoo CHE history; Bank of Canada daily FX; SEC ADUS and ROL FY2025 reports; quoted peer histories.

Verify figures in original filings and source index; this exhibit is not the original filing.